Companies / Guardian Pharmacy Services, Inc. / Activity
Activity — Guardian Pharmacy Services, Inc.
37 moves.
Top impactInsider · CEO movesInsider · biggest buysInsider · biggest sellsInstitution · biggest movesInstitution · new positions
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 20, 2026 | Salentine Thomas J Jr Director | Sell | Class A Common Stock | $105.99M | -3.6M -44.41% | 4,469,316 7.06% of shares | high |
| Mar 20, 2026 | Bindley Capital Partners I, LLC 10% owner | Sell | Class A Common Stock | $105.99M | -3.6M -44.41% | 4,469,316 7.06% of shares | high |
| Mar 20, 2026 | Bindley William E Director | Sell | Class A Common Stock | $105.99M | -3.6M -44.41% | 4,469,316 7.06% of shares | high |
| Mar 20, 2026 | Pharmacy Investors, LLC | Sell | Class A Common Stock | $24.57M | -828K -44.41% | 1,035,928 1.64% of shares | high |
| Mar 20, 2026 | Ackerman John Director | Sell | Class A Common Stock | $24.57M | -828K -44.41% | 1,035,928 1.64% of shares | high |
| Mar 20, 2026 | Burke Fred Executive | Sell | Class A Common Stock | $19.93M | -671K -44.41% | 840,413 1.33% of shares | high |
| Mar 20, 2026 | Forbes Kendall Executive | Sell | Class A Common Stock | $10.29M | -347K -43.34% | 453,256 0.72% of shares | medium |
| Mar 20, 2026 | Ackerman John Director | Sell | Class A Common Stock | $8.18M | -276K -44.41% | 345,123 0.54% of shares | medium |
| Mar 20, 2026 | Cardinal Equity Fund, L.P. | Sell | Class A Common Stock | $8.18M | -276K -44.41% | 345,123 0.54% of shares | medium |
| Mar 20, 2026 | Morris David K Executive | Sell | Class A Common Stock | $5.58M | -188K -42.47% | 254,472 0.40% of shares | medium |
| May 5, 2026 | Cosler Steven D Director | Grant | Class A Common Stock | $0 | +4K +16.12% | 29,012 0.05% of shares | low |
| May 5, 2026 | Lewis Randall J Director | Grant | Class A Common Stock | $0 | +4K +36.48% | 15,071 0.02% of shares | low |
| Mar 1, 2026 | Morris David K Executive | Grant | Class A Common Stock | $0 | +9K +2.07% | 442,327 0.70% of shares | low |
| Mar 1, 2026 | Forbes Kendall Executive | Grant | Class A Common Stock | $0 | +9K +1.13% | 799,928 1.26% of shares | low |
| Mar 28, 2026 | Pharmacy Investors, LLC | Exercise | Class B Common Stock | — | -1.4M -50.00% | 1,413,939 2.23% of shares | low |
| Mar 28, 2026 | Pharmacy Investors, LLC | Exercise | Class A Common Stock | — | +1.4M +136.49% | 2,449,867 3.87% of shares | low |
| Mar 28, 2026 | Bindley William E Director | Exercise | Class B Common Stock | — | -6.1M -50.00% | 6,100,175 9.63% of shares | low |
| Mar 28, 2026 | Bindley William E Director | Exercise | Class A Common Stock | — | +6.1M +136.49% | 10,569,491 16.69% of shares | low |
| Mar 28, 2026 | Cardinal Equity Fund, L.P. | Exercise | Class B Common Stock | — | -471K -50.00% | 471,057 0.74% of shares | low |
| Mar 28, 2026 | Cardinal Equity Fund, L.P. | Exercise | Class A Common Stock | — | +471K +136.49% | 816,180 1.29% of shares | low |
| Mar 28, 2026 | Salentine Thomas J Jr Director | Exercise | Class B Common Stock | — | -6.1M -50.00% | 6,100,175 9.63% of shares | low |
| Mar 28, 2026 | Salentine Thomas J Jr Director | Exercise | Class A Common Stock | — | +6.1M +136.49% | 10,569,491 16.69% of shares | low |
| Mar 28, 2026 | Forbes Kendall Executive | Exercise | Class B Common Stock | — | -609K -50.00% | 608,570 0.96% of shares | low |
| Mar 28, 2026 | Forbes Kendall Executive | Exercise | Class A Common Stock | — | +609K +134.27% | 1,061,826 1.68% of shares | low |
| Mar 28, 2026 | Morris David K Executive | Exercise | Class B Common Stock | — | -642K -50.00% | 641,870 1.01% of shares | low |
| Mar 28, 2026 | Morris David K Executive | Exercise | Class A Common Stock | — | +642K +252.24% | 896,341 1.42% of shares | low |
| Mar 28, 2026 | Bindley Capital Partners I, LLC 10% owner | Exercise | Class B Common Stock | — | -6.1M -50.00% | 6,100,175 9.63% of shares | low |
| Mar 28, 2026 | Bindley Capital Partners I, LLC 10% owner | Exercise | Class A Common Stock | — | +6.1M +136.49% | 10,569,491 16.69% of shares | low |
| Mar 28, 2026 | Ackerman John Director | Exercise | Class B Common Stock | — | -471K -50.00% | 471,057 0.74% of shares | low |
| Mar 28, 2026 | Ackerman John Director | Exercise | Class B Common Stock | — | -1.4M -50.00% | 1,413,939 2.23% of shares | low |
| Mar 28, 2026 | Ackerman John Director | Exercise | Class A Common Stock | — | +471K +136.49% | 816,180 1.29% of shares | low |
| Mar 28, 2026 | Ackerman John Director | Exercise | Class A Common Stock | — | +1.4M +136.49% | 2,449,867 3.87% of shares | low |
| Mar 28, 2026 | Burke Fred Executive | Exercise | Class B Common Stock | — | -1.3M -50.00% | 1,298,825 2.05% of shares | low |
| Mar 28, 2026 | Burke Fred Executive | Exercise | Class A Common Stock | — | +1.3M +154.55% | 2,139,239 3.38% of shares | low |
| Feb 11, 2026 | Forbes Kendall Executive | Grant | Stock Option (right to buy) | — | +50K | 50,000 0.08% of shares | low |
| Feb 11, 2026 | Burke Fred Executive | Grant | Stock Option (right to buy) | — | +75K | 75,000 0.12% of shares | low |
| Feb 11, 2026 | Morris David K Executive | Grant | Stock Option (right to buy) | — | +50K | 50,000 0.08% of shares | low |